DB06511ExperimentalProtein Based Therapies
Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.
- Primary indication
- Investigated for use/treatment in osteoporosis and bone metastases.Curator reviewed
- Also known as
- Osteoclastogenesis inhibitory factor · Osteoprotegerin recombinant · rOPG
- Code names
- AMGN-0007
Resolves to
Compound
Targets
What you can answer from here — as of March 06, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with AMGN-0007, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account